DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
LUCANTHONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LUCANTHONE
×
Maximum Phase:
2
First Approval:
None
UNII:
FC6D57000M
Molecule Type:
Small molecule
Molecular Formula:
C20H24N2OS
Molecular Weight:
340.49
AlogP:
4.48
PSA:
32.34
HBD:
1.0
HBA:
#RotB:
6.0
Source:
VESTIPITANT MESYLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Neurokinin 1 receptor antagonist
VESTIPITANT MESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
OWR424W90Q
Molecule Type:
Small molecule
Molecular Formula:
C24H28F7N3O4S
Molecular Weight:
587.56
AlogP:
5.93
PSA:
35.58
HBD:
1.0
HBA:
#RotB:
3.0
Source:
BATEFENTEROL
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Beta-2 adrenergic receptor agonist
BATEFENTEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
1IAT42T80T
Molecule Type:
Small molecule
Molecular Formula:
C40H42ClN5O7
Molecular Weight:
740.26
AlogP:
6.43
PSA:
165.25
HBD:
6.0
HBA:
#RotB:
13.0
Source:
GW-274150
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Arthritis, Rheumatoid; Migraine Disorders
Nitric oxide synthase, inducible inhibitor
GW-274150
×
Maximum Phase:
2
First Approval:
None
UNII:
0ZZF1V8G63
Molecule Type:
Small molecule
Molecular Formula:
C8H17N3O2S
Molecular Weight:
219.31
AlogP:
0.11
PSA:
99.2
HBD:
4.0
HBA:
#RotB:
7.0
Source:
IBUDILAST
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Glioblastoma; Migraine Disorders; Pain; Substance-Related Disorders; Alcoholism; Amphetamine-Related Disorders; Amyotrophic Lateral Sclerosis; Multiple Sclerosis, Chronic Progressive; Opioid-Related Disorders; Pneumonia, Viral; Lung Diseases, Obstructive; Spinal Cord Diseases
Phosphodiesterase 10A inhibitor
IBUDILAST
×
Maximum Phase:
2
First Approval:
None
UNII:
M0TTH61XC5
Molecule Type:
Small molecule
Molecular Formula:
C14H18N2O
Molecular Weight:
230.31
AlogP:
3.3
PSA:
34.37
HBD:
0.0
HBA:
#RotB:
3.0
Source:
BATABULIN
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular
Unknown
BATABULIN
×
Maximum Phase:
2
First Approval:
None
UNII:
T4NP8G3K6Q
Molecule Type:
Small molecule
Molecular Formula:
C13H7F6NO3S
Molecular Weight:
371.26
AlogP:
3.33
PSA:
55.4
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ROGARATINIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Neoplasms; Urinary Bladder Neoplasms
Fibroblast growth factor receptor inhibitor
ROGARATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
98BSN6N516
Molecule Type:
Small molecule
Molecular Formula:
C23H26N6O3S
Molecular Weight:
466.57
AlogP:
2.59
PSA:
107.01
HBD:
2.0
HBA:
#RotB:
6.0
Source:
IBEZAPOLSTAT
2
Small molecule
Investigational
Unknown
Unknown
Clostridium Infections
Unknown
IBEZAPOLSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
5K543KNC5P
Molecule Type:
Small molecule
Molecular Formula:
C18H20Cl2N6O2
Molecular Weight:
423.3
AlogP:
2.37
PSA:
88.07
HBD:
2.0
HBA:
#RotB:
6.0
Source:
NS-2359
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Depressive Disorder
Monoamine transporter inhibitor
NS-2359
×
Maximum Phase:
2
First Approval:
None
UNII:
76H76554PA
Molecule Type:
Small molecule
Molecular Formula:
C16H21Cl2NO
Molecular Weight:
314.26
AlogP:
4.21
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
3.0
Source:
F18-FFNP
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
F18-FFNP
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLUBENTYLOSIN
2
Small molecule
Investigational
Unknown
Unknown
Onchocerciasis
Unknown
FLUBENTYLOSIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C53H82FNO17
Molecular Weight:
1024.23
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
L-NAME
2
Small molecule
Investigational
Unknown
Unknown
Cardiovascular Diseases; Asthma
Unknown
L-NAME
×
Maximum Phase:
2
First Approval:
None
UNII:
V55S2QJN2X
Molecule Type:
Small molecule
Molecular Formula:
C7H15N5O4
Molecular Weight:
233.23
AlogP:
-1.43
PSA:
143.37
HBD:
4.0
HBA:
#RotB:
6.0
Source:
SONOLISIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Glioblastoma; Prostatic Neoplasms, Castration-Resistant
PI3-kinase class I inhibitor
SONOLISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
987796874T
Molecule Type:
Small molecule
Molecular Formula:
C29H35NO8
Molecular Weight:
525.6
AlogP:
3.13
PSA:
119.44
HBD:
1.0
HBA:
#RotB:
8.0
Source:
CC-115
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Squamous Cell; Glioblastoma; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Osteosarcoma; Prostatic Neoplasms, Castration-Resistant
DNA-dependent protein kinase inhibitor
CC-115
×
Maximum Phase:
2
First Approval:
None
UNII:
FII75TFH5L
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MANITIMUS
2
Small molecule
Investigational
Unknown
Unknown
Graft vs Host Disease; Kidney Diseases
Unknown
MANITIMUS
×
Maximum Phase:
2
First Approval:
None
UNII:
4B135RK2KL
Molecule Type:
Small molecule
Molecular Formula:
C14H10F3N3O2
Molecular Weight:
309.25
AlogP:
3.28
PSA:
96.91
HBD:
2.0
HBA:
#RotB:
4.0
Source:
E7449
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
E7449
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PBF-680
2
Small molecule
Investigational
Unknown
Unknown
Asthma
Adenosine A1 receptor antagonist
PBF-680
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALAGEBRIUM
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure, Diastolic
Unknown
ALAGEBRIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
DGH49JXB1F
Molecule Type:
Small molecule
Molecular Formula:
C13H14NOS+
Molecular Weight:
232.33
AlogP:
2.54
PSA:
20.95
HBD:
0.0
HBA:
#RotB:
3.0
Source:
PAGOCLONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
GABA-A receptor; anion channel positive allosteric modulator
PAGOCLONE
×
Maximum Phase:
2
First Approval:
None
UNII:
38VAG2SA33
Molecule Type:
Small molecule
Molecular Formula:
C23H22ClN3O2
Molecular Weight:
407.9
AlogP:
5.38
PSA:
63.16
HBD:
0.0
HBA:
#RotB:
6.0
Source:
RADALBUVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
RADALBUVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
273K4V0SPC
Molecule Type:
Small molecule
Molecular Formula:
C30H41NO6S
Molecular Weight:
543.73
AlogP:
5.4
PSA:
96.3
HBD:
2.0
HBA:
#RotB:
7.0
Source:
OSORESNONTRINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Mental Disorders; Schizophrenia
Unknown
OSORESNONTRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
O9OC34WOAY
Molecule Type:
Small molecule
Molecular Formula:
C16H17N5O2
Molecular Weight:
311.35
AlogP:
1.46
PSA:
85.69
HBD:
1.0
HBA:
#RotB:
3.0
Source:
VILANTEROL .ALPHA.-PHENYL CINNAMATE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
VILANTEROL .ALPHA.-PHENYL CINNAMATE
×
Maximum Phase:
2
First Approval:
None
UNII:
DB71X3OVN2
Molecule Type:
Small molecule
Molecular Formula:
C39H45Cl2NO7
Molecular Weight:
710.7
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
NEPICASTAT
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders; Stress Disorders, Post-Traumatic
Unknown
NEPICASTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
VPG12K4540
Molecule Type:
Small molecule
Molecular Formula:
C14H15F2N3S
Molecular Weight:
295.36
AlogP:
2.64
PSA:
43.84
HBD:
2.0
HBA:
#RotB:
2.0
Source:
CINACIGUAT
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure
Soluble guanylate cyclase activator
CINACIGUAT
×
Maximum Phase:
2
First Approval:
None
UNII:
59K0Y58UAD
Molecule Type:
Small molecule
Molecular Formula:
C36H39NO5
Molecular Weight:
565.71
AlogP:
7.05
PSA:
87.07
HBD:
2.0
HBA:
#RotB:
17.0
Source:
RALMITARONT
2
Small molecule
Investigational
Unknown
Unknown
Psychotic Disorders
Unknown
RALMITARONT
×
Maximum Phase:
2
First Approval:
None
UNII:
QA8MW1Q80P
Molecule Type:
Small molecule
Molecular Formula:
C17H22N4O2
Molecular Weight:
314.39
AlogP:
2.19
PSA:
79.04
HBD:
3.0
HBA:
#RotB:
4.0
Source:
SOTRASTAURIN
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Lymphoma, Large B-Cell, Diffuse; Colitis, Ulcerative; Psoriasis; Uveitis, Posterior
Protein kinase C (PKC) inhibitor
SOTRASTAURIN
×
Maximum Phase:
2
First Approval:
None
UNII:
7I279E1NZ8
Molecule Type:
Small molecule
Molecular Formula:
C25H22N6O2
Molecular Weight:
438.49
AlogP:
2.43
PSA:
94.22
HBD:
2.0
HBA:
#RotB:
3.0
Source:
FILOREXANT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major; Diabetic Neuropathies; Sleep Initiation and Maintenance Disorders
Orexin receptor antagonist
FILOREXANT
×
Maximum Phase:
2
First Approval:
None
UNII:
E6BTT8VA5Z
Molecule Type:
Small molecule
Molecular Formula:
C24H25FN4O2
Molecular Weight:
420.49
AlogP:
4.31
PSA:
68.21
HBD:
0.0
HBA:
#RotB:
5.0
Source:
O-CHLOROACETYLCARBAMOYLFUMAGILLOL
2
Small molecule
Investigational
Unknown
Unknown
Pancreatic Neoplasms
Unknown
O-CHLOROACETYLCARBAMOYLFUMAGILLOL
×
Maximum Phase:
2
First Approval:
None
UNII:
X47GR46481
Molecule Type:
Small molecule
Molecular Formula:
C19H28ClNO6
Molecular Weight:
401.89
AlogP:
2.55
PSA:
89.69
HBD:
1.0
HBA:
#RotB:
6.0
Source:
GW590735
2
Small molecule
Investigational
Unknown
Unknown
Lipid Metabolism Disorders
Peroxisome proliferator-activated receptor alpha agonist
GW590735
×
Maximum Phase:
2
First Approval:
None
UNII:
QKY617BBX5
Molecule Type:
Small molecule
Molecular Formula:
C23H21F3N2O4S
Molecular Weight:
478.49
AlogP:
5.31
PSA:
88.52
HBD:
2.0
HBA:
#RotB:
7.0
Source:
STG-001
2
Small molecule
Investigational
Unknown
Unknown
Stargardt Disease
Unknown
STG-001
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C14H10F6N2O2
Molecular Weight:
352.23
AlogP:
4.06
PSA:
55.12
HBD:
1.0
HBA:
#RotB:
4.0
Source:
UK-390957
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UK-390957
×
Maximum Phase:
2
First Approval:
None
UNII:
W26I0D1D6J
Molecule Type:
Small molecule
Molecular Formula:
C16H20N2O3S2
Molecular Weight:
352.48
AlogP:
2.91
PSA:
72.63
HBD:
1.0
HBA:
#RotB:
6.0
Source:
CHF-6001
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitor
CHF-6001
×
Maximum Phase:
2
First Approval:
None
UNII:
0984EU6E2F
Molecule Type:
Small molecule
Molecular Formula:
C30H30Cl2F2N2O8S
Molecular Weight:
687.54
AlogP:
6.32
PSA:
127.1
HBD:
1.0
HBA:
#RotB:
15.0
Source:
TAS-117
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Serine/threonine-protein kinase AKT negative allosteric modulator
TAS-117
×
Maximum Phase:
2
First Approval:
None
UNII:
QI52W1ZIIB
Molecule Type:
Small molecule
Molecular Formula:
C26H24N4O2
Molecular Weight:
424.5
AlogP:
4.33
PSA:
86.19
HBD:
2.0
HBA:
#RotB:
3.0
Source:
7-ETHYL-10-HYDROXYCAMPTOTHECIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Small Cell Lung Carcinoma
DNA topoisomerase I inhibitor
7-ETHYL-10-HYDROXYCAMPTOTHECIN
×
Maximum Phase:
2
First Approval:
None
UNII:
0H43101T0J
Molecule Type:
Small molecule
Molecular Formula:
C22H20N2O5
Molecular Weight:
392.41
AlogP:
2.35
PSA:
101.65
HBD:
2.0
HBA:
#RotB:
2.0
Source:
REFAMETINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
REFAMETINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
JPX07AFM0N
Molecule Type:
Small molecule
Molecular Formula:
C19H20F3IN2O5S
Molecular Weight:
572.34
AlogP:
3.48
PSA:
107.89
HBD:
4.0
HBA:
#RotB:
9.0
Source:
1
2
…
123
124
125
126
127
128
129
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA